Tamibarotene
Tamibarotene
Tamibarotene:
Tamibarotene (brand name: Amnolake), also called retinobenzoic acid, is orally active, synthetic retinoid, developed to overcome all-trans retinoic acid (ATRA) resi
Myelodysplastic Syndromes (MDS)
SY-1425
SY-1425
SY-1425:
SY-1425 is a selective retinoic acid receptor alpha (RARα) agonist for genomically defined subsets of patients whose disease is characterized by the overexpression of the RARA gene.
Germline mutations in MDS/AML predisposition disorders
Purpose of review: Recognition of hereditary hematopoietic malignancies impacts patient management as well as health surveillance strategies for the patient and relatives who share the causative DNA variant. In this review, barriers to the diagnosis and management of patients are outlined.
Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management"
Disease overview: Ring sideroblasts (RS) are erythroid precursors with abnormal perinuclear mitochondrial iron accumulation.
Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors
We compared outcomes in 603 patients with myelodysplastic syndrome (MDS) after HLA HLA: See human leukocyte antigen. -haploidentical relative (n = 176) and HLA-matched unrelated (n = 427) donor hematopoietic cell transplan
Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes
Hypomethylating agents (HMAs) are widely used in the treatment of myelodysplastic syndromes myelodysplastic syndromes: (my-eh
Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)
Purpose: TP53-mutated (TP53m) myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS
Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantat
Background: Immune checkpoint inhibitors (ICIs) are being used after allogeneic hematopoietic stem cell transplantation (alloHCT) to reverse immune dysfunction.
Joshua Zeidner, MD
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
About
Dr. Zeidner's research interests include discovering innovative methods to improve outcomes, drug discovery and development, and designing clinical trials in acute myeloid leukemia (AML) myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs). He leads the Leukemia Clinical Trials Research Protocol Office Disease (POD) Group where we have a multitude of cutting-edge clinical trials for acute leukemia, MDS, and MPNs. Dr. Zeidner's the Principal Investigator of industry-sponsored, investigator-initiated, and academic collaborative clinical trials evaluating novel agents in MDS
Katherine Tarlock, MD
Institution
Seattle Children's Hospital
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Pediatric
About
Katherine Tarlock, M.D., is a board certified physician at Seattle Children’s Hospital and a UW assistant professor of pediatrics. Dr. Tarlock believes the privilege of caring for patients and families during challenging medical diagnoses is what drew her to this field and continues to be the best part of her job. She is dedicated to advancing our understanding of leukemia and being able to offer every child and family the best care. Dr. Tarlock earned her M.D. at Chicago Medical School. She is board certified in both Pediatrics and Pediatric Hematology/Oncology.